APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Proteins and Oral Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Therapeutic Proteins and Oral Vaccines Market Analysis and Forecast 2026-2032

Report ID 174040790230 December 2025192 pages

Choose your research edition.

Industry ResearchTherapeutic Proteins and Oral Vaccines Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Proteins and Oral Vaccines Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Therapeutic Proteins and Oral Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Proteins and Oral Vaccines Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Proteins and Oral Vaccines Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Therapeutic Proteins and Oral Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Therapeutic Proteins and Oral Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Therapeutic Proteins and Oral Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Therapeutic Proteins and Oral Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Therapeutic Proteins and Oral Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Therapeutic Proteins and Oral Vaccines include Abbott, Sanofi, Merck, Roche, Pfizer, Amgen, TransAlgae, Serum Institute of India and Novo Nordisk, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Therapeutic Proteins and Oral Vaccines, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Therapeutic Proteins and Oral Vaccines, also provides the revenue of main regions and countries. Of the upcoming market potential for Therapeutic Proteins and Oral Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Therapeutic Proteins and Oral Vaccines revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Therapeutic Proteins and Oral Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Therapeutic Proteins and Oral Vaccines revenue, projected growth trends, production technology, application and end-user industry.

Therapeutic Proteins and Oral Vaccines Segment by Company

Abbott

Sanofi

Merck

Roche

Pfizer

Amgen

TransAlgae

Serum Institute of India

Novo Nordisk

MigVax

Lumen Bioscience

Johnson and Johnson

Emergent Biosolutions

Eli Lilly and Company

Biogen

Therapeutic Proteins and Oral Vaccines Segment by Type

Therapeutic Proteins

Oral Vaccines

Therapeutic Proteins and Oral Vaccines Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Therapeutic Proteins and Oral Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Proteins and Oral Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Proteins and Oral Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Proteins and Oral Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Therapeutic Proteins and Oral Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Therapeutic Proteins and Oral Vaccines company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Therapeutic Proteins and Oral Vaccines revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Therapeutic Proteins and Oral Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Therapeutic Proteins Major Player Table 3. Oral Vaccines Major Player Table 4. Global Therapeutic Proteins and Oral Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Retail Pharmacies Major Player Table 6. Online Pharmacies Major Player Table 7. Hospital Pharmacies Major Player Table 8. Therapeutic Proteins and Oral Vaccines Industry Trends Table 9. Therapeutic Proteins and Oral Vaccines Industry Drivers Table 10. Therapeutic Proteins and Oral Vaccines Industry Opportunities and Challenges Table 11. Therapeutic Proteins and Oral Vaccines Industry Restraints Table 12. Global Therapeutic Proteins and Oral Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Therapeutic Proteins and Oral Vaccines Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Therapeutic Proteins and Oral Vaccines Market Share by Region (2021-2026) Table 15. Global Therapeutic Proteins and Oral Vaccines Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Therapeutic Proteins and Oral Vaccines Market Share by Region (2027-2032) Table 17. Global Therapeutic Proteins and Oral Vaccines Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Therapeutic Proteins and Oral Vaccines Revenue Market Share by Players (2021-2026) Table 19. Global Therapeutic Proteins and Oral Vaccines Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Therapeutic Proteins and Oral Vaccines Key Players Headquarters & Area Served Table 21. Global Therapeutic Proteins and Oral Vaccines Players, Product Type & Application Table 22. Global Therapeutic Proteins and Oral Vaccines Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Therapeutic Proteins and Oral Vaccines by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Therapeutic Proteins and Oral Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Therapeutic Proteins and Oral Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Therapeutic Proteins and Oral Vaccines Revenue Market Share by Type (2021-2026) Table 29. Global Therapeutic Proteins and Oral Vaccines Revenue Market Share by Type (2027-2032) Table 30. Global Therapeutic Proteins and Oral Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Therapeutic Proteins and Oral Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Therapeutic Proteins and Oral Vaccines Revenue Market Share by Application (2021-2026) Table 34. Global Therapeutic Proteins and Oral Vaccines Revenue Market Share by Application (2027-2032) Table 35. Abbott Company Information Table 36. Abbott Business Overview Table 37. Abbott Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Abbott Therapeutic Proteins and Oral Vaccines Product Portfolio Table 39. Abbott Recent Development Table 40. Sanofi Company Information Table 41. Sanofi Business Overview Table 42. Sanofi Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Sanofi Therapeutic Proteins and Oral Vaccines Product Portfolio Table 44. Sanofi Recent Development Table 45. Merck Company Information Table 46. Merck Business Overview Table 47. Merck Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Merck Therapeutic Proteins and Oral Vaccines Product Portfolio Table 49. Merck Recent Development Table 50. Roche Company Information Table 51. Roche Business Overview Table 52. Roche Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Roche Therapeutic Proteins and Oral Vaccines Product Portfolio Table 54. Roche Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Pfizer Therapeutic Proteins and Oral Vaccines Product Portfolio Table 59. Pfizer Recent Development Table 60. Amgen Company Information Table 61. Amgen Business Overview Table 62. Amgen Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Amgen Therapeutic Proteins and Oral Vaccines Product Portfolio Table 64. Amgen Recent Development Table 65. TransAlgae Company Information Table 66. TransAlgae Business Overview Table 67. TransAlgae Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. TransAlgae Therapeutic Proteins and Oral Vaccines Product Portfolio Table 69. TransAlgae Recent Development Table 70. Serum Institute of India Company Information Table 71. Serum Institute of India Business Overview Table 72. Serum Institute of India Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Serum Institute of India Therapeutic Proteins and Oral Vaccines Product Portfolio Table 74. Serum Institute of India Recent Development Table 75. Novo Nordisk Company Information Table 76. Novo Nordisk Business Overview Table 77. Novo Nordisk Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Novo Nordisk Therapeutic Proteins and Oral Vaccines Product Portfolio Table 79. Novo Nordisk Recent Development Table 80. MigVax Company Information Table 81. MigVax Business Overview Table 82. MigVax Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. MigVax Therapeutic Proteins and Oral Vaccines Product Portfolio Table 84. MigVax Recent Development Table 85. Lumen Bioscience Company Information Table 86. Lumen Bioscience Business Overview Table 87. Lumen Bioscience Therapeutic Proteins and Oral Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Lumen Bioscience Therapeutic Proteins and Oral Vaccines Product Portfolio Table 89. Lumen Bioscience Recent Development Table 90. Johnson and Johnson Company Information Table 91. Johnson and Johnson Business Overview Table 92. Johnson and Johnson Therapeutic Proteins and Oral Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Johnson and Johnson Therapeutic Proteins and Oral Vaccines Product Portfolio Table 94. Johnson and Johnson Recent Development Table 95. Emergent Biosolutions Company Information Table 96. Emergent Biosolutions Business Overview Table 97. Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Product Portfolio Table 99. Emergent Biosolutions Recent Development Table 100. Eli Lilly and Company Company Information Table 101. Eli Lilly and Company Business Overview Table 102. Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Product Portfolio Table 104. Eli Lilly and Company Recent Development Table 105. Biogen Company Information Table 106. Biogen Business Overview Table 107. Biogen Therapeutic Proteins and Oral Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Biogen Therapeutic Proteins and Oral Vaccines Product Portfolio Table 109. Biogen Recent Development Table 110. North America Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 111. North America Therapeutic Proteins and Oral Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 112. North America Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 113. North America Therapeutic Proteins and Oral Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 114. North America Therapeutic Proteins and Oral Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Therapeutic Proteins and Oral Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Therapeutic Proteins and Oral Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 117. Europe Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 118. Europe Therapeutic Proteins and Oral Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 119. Europe Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 120. Europe Therapeutic Proteins and Oral Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 121. Europe Therapeutic Proteins and Oral Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe Therapeutic Proteins and Oral Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 123. Europe Therapeutic Proteins and Oral Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 124. China Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 125. China Therapeutic Proteins and Oral Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 126. China Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 127. China Therapeutic Proteins and Oral Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 129. Asia Therapeutic Proteins and Oral Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 130. Asia Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 131. Asia Therapeutic Proteins and Oral Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Therapeutic Proteins and Oral Vaccines Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Asia Therapeutic Proteins and Oral Vaccines Revenue by Region (US$ Million) & (2021-2026) Table 134. Asia Therapeutic Proteins and Oral Vaccines Revenue by Region (US$ Million) & (2027-2032) Table 135. SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 136. SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 137. SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 138. SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 139. SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 141. SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Therapeutic Proteins and Oral Vaccines Image Figure 2. Global Therapeutic Proteins and Oral Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Proteins and Oral Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Therapeutic Proteins Image Figure 5. Oral Vaccines Image Figure 6. Global Therapeutic Proteins and Oral Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Therapeutic Proteins and Oral Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 8. Retail Pharmacies Image Figure 9. Online Pharmacies Image Figure 10. Hospital Pharmacies Image Figure 11. Global Therapeutic Proteins and Oral Vaccines Market Size (US$ Million) & (2021-2032) Figure 12. Global Therapeutic Proteins and Oral Vaccines Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Therapeutic Proteins and Oral Vaccines Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Therapeutic Proteins and Oral Vaccines Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Therapeutic Proteins and Oral Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Therapeutic Proteins and Oral Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Therapeutic Proteins and Oral Vaccines Revenue Market Share by Type (2021-2032) Figure 19. Global Therapeutic Proteins and Oral Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Therapeutic Proteins and Oral Vaccines Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Therapeutic Proteins and Oral Vaccines Revenue Market Share by Application (2021-2032) Figure 22. North America Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Therapeutic Proteins and Oral Vaccines Revenue Share by Type (2021-2032) Figure 24. North America Therapeutic Proteins and Oral Vaccines Revenue Share by Application (2021-2032) Figure 25. North America Therapeutic Proteins and Oral Vaccines Revenue Share by Country (2021-2032) Figure 26. United States Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Therapeutic Proteins and Oral Vaccines Revenue Share by Type (2021-2032) Figure 31. Europe Therapeutic Proteins and Oral Vaccines Revenue Share by Application (2021-2032) Figure 32. Europe Therapeutic Proteins and Oral Vaccines Revenue Share by Country (2021-2032) Figure 33. Germany Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Therapeutic Proteins and Oral Vaccines Revenue Share by Type (2021-2032) Figure 43. China Therapeutic Proteins and Oral Vaccines Revenue Share by Application (2021-2032) Figure 44. Asia Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Therapeutic Proteins and Oral Vaccines Revenue Share by Type (2021-2032) Figure 46. Asia Therapeutic Proteins and Oral Vaccines Revenue Share by Application (2021-2032) Figure 47. Asia Therapeutic Proteins and Oral Vaccines Revenue Share by Region (2021-2032) Figure 48. Japan Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Therapeutic Proteins and Oral Vaccines Revenue Share by Type (2021-2032) Figure 56. SAMEA Therapeutic Proteins and Oral Vaccines Revenue Share by Application (2021-2032) Figure 57. SAMEA Therapeutic Proteins and Oral Vaccines Revenue Share by Country (2021-2032) Figure 58. Brazil Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Therapeutic Proteins and Oral Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Therapeutic Proteins
  • Oral Vaccines
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Abbott
  • Sanofi
  • Merck
  • Roche
  • Pfizer
  • Amgen
  • TransAlgae
  • Serum Institute of India
  • Novo Nordisk
  • MigVax
  • Lumen Bioscience
  • Johnson and Johnson
  • Emergent Biosolutions
  • Eli Lilly and Company
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Therapeutic Proteins and Oral Vaccines Market by Type
  3. 1.2.1 Global Therapeutic Proteins and Oral Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Therapeutic Proteins
  5. 1.2.3 Oral Vaccines
  6. 1.3 Therapeutic Proteins and Oral Vaccines Market by Application
  7. 1.3.1 Global Therapeutic Proteins and Oral Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Retail Pharmacies
  9. 1.3.3 Online Pharmacies
  10. 1.3.4 Hospital Pharmacies
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Therapeutic Proteins and Oral Vaccines Market Dynamics
  1. 2.1 Therapeutic Proteins and Oral Vaccines Industry Trends
  2. 2.2 Therapeutic Proteins and Oral Vaccines Industry Drivers
  3. 2.3 Therapeutic Proteins and Oral Vaccines Industry Opportunities and Challenges
  4. 2.4 Therapeutic Proteins and Oral Vaccines Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Therapeutic Proteins and Oral Vaccines Market Perspective (2021-2032)
  2. 3.2 Global Therapeutic Proteins and Oral Vaccines Growth Trends by Region
  3. 3.2.1 Global Therapeutic Proteins and Oral Vaccines Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Therapeutic Proteins and Oral Vaccines Market Size by Region (2021-2026)
  5. 3.2.3 Global Therapeutic Proteins and Oral Vaccines Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Therapeutic Proteins and Oral Vaccines Revenue by Players
  2. 4.1.1 Global Therapeutic Proteins and Oral Vaccines Revenue by Players (2021-2026)
  3. 4.1.2 Global Therapeutic Proteins and Oral Vaccines Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Therapeutic Proteins and Oral Vaccines Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Therapeutic Proteins and Oral Vaccines Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Therapeutic Proteins and Oral Vaccines Key Players Headquarters & Area Served
  7. 4.4 Global Therapeutic Proteins and Oral Vaccines Players, Product Type & Application
  8. 4.5 Global Therapeutic Proteins and Oral Vaccines Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Therapeutic Proteins and Oral Vaccines Market CR5 and HHI
  11. 4.6.3 2025 Therapeutic Proteins and Oral Vaccines Tier 1, Tier 2, and Tier 3
5 Therapeutic Proteins and Oral Vaccines Market Size by Type
  1. 5.1 Global Therapeutic Proteins and Oral Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2032)
  3. 5.3 Global Therapeutic Proteins and Oral Vaccines Revenue Market Share by Type (2021-2032)
6 Therapeutic Proteins and Oral Vaccines Market Size by Application
  1. 6.1 Global Therapeutic Proteins and Oral Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2032)
  3. 6.3 Global Therapeutic Proteins and Oral Vaccines Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abbott
  2. 7.1.1 Abbott Company Information
  3. 7.1.2 Abbott Business Overview
  4. 7.1.3 Abbott Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abbott Therapeutic Proteins and Oral Vaccines Product Portfolio
  6. 7.1.5 Abbott Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Therapeutic Proteins and Oral Vaccines Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck Therapeutic Proteins and Oral Vaccines Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 Roche
  20. 7.4.1 Roche Company Information
  21. 7.4.2 Roche Business Overview
  22. 7.4.3 Roche Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Roche Therapeutic Proteins and Oral Vaccines Product Portfolio
  24. 7.4.5 Roche Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Therapeutic Proteins and Oral Vaccines Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Amgen
  32. 7.6.1 Amgen Company Information
  33. 7.6.2 Amgen Business Overview
  34. 7.6.3 Amgen Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Amgen Therapeutic Proteins and Oral Vaccines Product Portfolio
  36. 7.6.5 Amgen Recent Developments
  37. 7.7 TransAlgae
  38. 7.7.1 TransAlgae Company Information
  39. 7.7.2 TransAlgae Business Overview
  40. 7.7.3 TransAlgae Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  41. 7.7.4 TransAlgae Therapeutic Proteins and Oral Vaccines Product Portfolio
  42. 7.7.5 TransAlgae Recent Developments
  43. 7.8 Serum Institute of India
  44. 7.8.1 Serum Institute of India Company Information
  45. 7.8.2 Serum Institute of India Business Overview
  46. 7.8.3 Serum Institute of India Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Serum Institute of India Therapeutic Proteins and Oral Vaccines Product Portfolio
  48. 7.8.5 Serum Institute of India Recent Developments
  49. 7.9 Novo Nordisk
  50. 7.9.1 Novo Nordisk Company Information
  51. 7.9.2 Novo Nordisk Business Overview
  52. 7.9.3 Novo Nordisk Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Novo Nordisk Therapeutic Proteins and Oral Vaccines Product Portfolio
  54. 7.9.5 Novo Nordisk Recent Developments
  55. 7.10 MigVax
  56. 7.10.1 MigVax Company Information
  57. 7.10.2 MigVax Business Overview
  58. 7.10.3 MigVax Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  59. 7.10.4 MigVax Therapeutic Proteins and Oral Vaccines Product Portfolio
  60. 7.10.5 MigVax Recent Developments
  61. 7.11 Lumen Bioscience
  62. 7.11.1 Lumen Bioscience Company Information
  63. 7.11.2 Lumen Bioscience Business Overview
  64. 7.11.3 Lumen Bioscience Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Lumen Bioscience Therapeutic Proteins and Oral Vaccines Product Portfolio
  66. 7.11.5 Lumen Bioscience Recent Developments
  67. 7.12 Johnson and Johnson
  68. 7.12.1 Johnson and Johnson Company Information
  69. 7.12.2 Johnson and Johnson Business Overview
  70. 7.12.3 Johnson and Johnson Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Johnson and Johnson Therapeutic Proteins and Oral Vaccines Product Portfolio
  72. 7.12.5 Johnson and Johnson Recent Developments
  73. 7.13 Emergent Biosolutions
  74. 7.13.1 Emergent Biosolutions Company Information
  75. 7.13.2 Emergent Biosolutions Business Overview
  76. 7.13.3 Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Product Portfolio
  78. 7.13.5 Emergent Biosolutions Recent Developments
  79. 7.14 Eli Lilly and Company
  80. 7.14.1 Eli Lilly and Company Company Information
  81. 7.14.2 Eli Lilly and Company Business Overview
  82. 7.14.3 Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Product Portfolio
  84. 7.14.5 Eli Lilly and Company Recent Developments
  85. 7.15 Biogen
  86. 7.15.1 Biogen Company Information
  87. 7.15.2 Biogen Business Overview
  88. 7.15.3 Biogen Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Biogen Therapeutic Proteins and Oral Vaccines Product Portfolio
  90. 7.15.5 Biogen Recent Developments
8 North America
  1. 8.1 North America Therapeutic Proteins and Oral Vaccines Revenue (2021-2032)
  2. 8.2 North America Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2032)
  3. 8.2.1 North America Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2026)
  4. 8.2.2 North America Therapeutic Proteins and Oral Vaccines Revenue by Type (2027-2032)
  5. 8.3 North America Therapeutic Proteins and Oral Vaccines Revenue Share by Type (2021-2032)
  6. 8.4 North America Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2032)
  7. 8.4.1 North America Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2026)
  8. 8.4.2 North America Therapeutic Proteins and Oral Vaccines Revenue by Application (2027-2032)
  9. 8.5 North America Therapeutic Proteins and Oral Vaccines Revenue Share by Application (2021-2032)
  10. 8.6 North America Therapeutic Proteins and Oral Vaccines Revenue by Country
  11. 8.6.1 North America Therapeutic Proteins and Oral Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Therapeutic Proteins and Oral Vaccines Revenue by Country (2021-2026)
  13. 8.6.3 North America Therapeutic Proteins and Oral Vaccines Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Therapeutic Proteins and Oral Vaccines Revenue (2021-2032)
  2. 9.2 Europe Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2032)
  3. 9.2.1 Europe Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2026)
  4. 9.2.2 Europe Therapeutic Proteins and Oral Vaccines Revenue by Type (2027-2032)
  5. 9.3 Europe Therapeutic Proteins and Oral Vaccines Revenue Share by Type (2021-2032)
  6. 9.4 Europe Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2032)
  7. 9.4.1 Europe Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2026)
  8. 9.4.2 Europe Therapeutic Proteins and Oral Vaccines Revenue by Application (2027-2032)
  9. 9.5 Europe Therapeutic Proteins and Oral Vaccines Revenue Share by Application (2021-2032)
  10. 9.6 Europe Therapeutic Proteins and Oral Vaccines Revenue by Country
  11. 9.6.1 Europe Therapeutic Proteins and Oral Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Therapeutic Proteins and Oral Vaccines Revenue by Country (2021-2026)
  13. 9.6.3 Europe Therapeutic Proteins and Oral Vaccines Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Therapeutic Proteins and Oral Vaccines Revenue (2021-2032)
  2. 10.2 China Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2032)
  3. 10.2.1 China Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2026)
  4. 10.2.2 China Therapeutic Proteins and Oral Vaccines Revenue by Type (2027-2032)
  5. 10.3 China Therapeutic Proteins and Oral Vaccines Revenue Share by Type (2021-2032)
  6. 10.4 China Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2032)
  7. 10.4.1 China Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2026)
  8. 10.4.2 China Therapeutic Proteins and Oral Vaccines Revenue by Application (2027-2032)
  9. 10.5 China Therapeutic Proteins and Oral Vaccines Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Therapeutic Proteins and Oral Vaccines Revenue (2021-2032)
  2. 11.2 Asia Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2032)
  3. 11.2.1 Asia Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2026)
  4. 11.2.2 Asia Therapeutic Proteins and Oral Vaccines Revenue by Type (2027-2032)
  5. 11.3 Asia Therapeutic Proteins and Oral Vaccines Revenue Share by Type (2021-2032)
  6. 11.4 Asia Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2032)
  7. 11.4.1 Asia Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2026)
  8. 11.4.2 Asia Therapeutic Proteins and Oral Vaccines Revenue by Application (2027-2032)
  9. 11.5 Asia Therapeutic Proteins and Oral Vaccines Revenue Share by Application (2021-2032)
  10. 11.6 Asia Therapeutic Proteins and Oral Vaccines Revenue by Country
  11. 11.6.1 Asia Therapeutic Proteins and Oral Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Therapeutic Proteins and Oral Vaccines Revenue by Country (2021-2026)
  13. 11.6.3 Asia Therapeutic Proteins and Oral Vaccines Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Therapeutic Proteins and Oral Vaccines Revenue (2021-2032)
  2. 12.2 SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Type (2027-2032)
  5. 12.3 SAMEA Therapeutic Proteins and Oral Vaccines Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Application (2027-2032)
  9. 12.5 SAMEA Therapeutic Proteins and Oral Vaccines Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Country
  11. 12.6.1 SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Therapeutic Proteins and Oral Vaccines Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst